Patients - More Great Research Trimel is going to be discovered by the market one of these days. 70% of patients would switch from competitors! 84% found administration easy. 42% felt better on Compleo than on other T-replacement products.
Trimel Reports Positive CompleoTRT(TM) Patient Market Research Results
42% of those previously treated with a testosterone replacement therapy felt better on CompleoTRT(TM) - 70% previously treated with a testosterone replacement therapy would stay on CompleoTRT(TM) - 84% were confident in administering CompleoTRT(TM) within 2 days
TORONTO, ONTARIO--(Marketwire - Jan. 7, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) (the "Company" or "Trimel") today announced positive results from a recently completed market research study that surveyed patients who participated in the CompleoTRT™ Phase III efficacy study.
The quantitative study conducted in the United States surveyed 99 patients who had a minimum of 90 days of CompleoTRT™ treatment, 50 of whom were previously treated with another testosterone replacement therapy. Respondents participated on a voluntary basis, with the survey administered by the contract research organization responsible for conducting the Phase III trial. Patients were asked questions specific to their experience with administering CompleoTRT™ on a daily basis and were asked to assess, if applicable, how their experience with CompleoTRT™ compared to that of their previous testosterone therapies.
For those patients who had previous experience with other testosterone replacement therapies, 42% indicated that they felt better on CompleoTRT™ as compared to their previous experience, while 34% felt the same. When asked if they would use CompleoTRT™ if it were approved and available by prescription, 70% of those who were previously treated with a testosterone replacement therapy would adopt CompleoTRT™ rather than return to their previous therapy.
Finally, 84% of the patients participating in the survey were confident in applying CompleoTRT™ intranasally within 2 days of initiating therapy during the trial.
Tom Rossi, President and Chief Executive Officer, offered the following comment: "These positive findings further corroborate the feedback we received from our recently announced physician independent market research study. Physicians surveyed recognized the advantages of CompleoTRT™ and indicated a willingness to prescribe it to a good percentage of their Low T patients. As well, most patients who participated in the patient market research study indicated they would prefer it over other products they have used in the past. These two findings, together, provide further support for the tremendous opportunity that CompleoTRT™ could represent in a rapidly growing testosterone market starved for innovation."